Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.79
-0.55 (-3.17%)
Jun 8, 2026, 1:52 PM EDT - Market open
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $64.86M in the quarter ending March 31, 2026, with 223.64% growth. This brings the company's revenue in the last twelve months to $217.42M, up 397.28% year-over-year. In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth.
Revenue (ttm)
$217.42M
Revenue Growth
+397.28%
P/S Ratio
6.96
Revenue / Employee
$728,772
Employees
298
Market Cap
1.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Novavax | 596.34M |
| AnaptysBio | 232.39M |
| Nurix Therapeutics | 71.78M |
| Capricor Therapeutics | 11.13M |
| Taysha Gene Therapies | 7.47M |
SNDX News
- 3 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 days ago - Syndax Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 days ago - Syndax announces $250M convertible senior note offering due 2031 - TheFly
- 4 days ago - Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - GlobeNewsWire
- 5 days ago - Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - GlobeNewsWire
- 7 days ago - Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - GlobeNewsWire
- 12 days ago - Syndax Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts